International: +1-347-960-6455

Research Reports

Filter By Therapeutic Area

Filtered by Therapeutic Areas (Metabolic)

Metabolic
Niemann-Pick Disease Type C (NPC) Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations and Other Developments
Report Category Competitive Landscape Reports

Niemann–Pick type C (NPC) disease is a rare progressive genetic disorder, characterized by the inability of the body to transport lipids and cholesterol inside the cells.

Metabolic
Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

NF-κB is identified as a family of highly conserved transcription factors, which are responsible for many cellular functions such as regulation of inflammatory responses, apoptosis, cellular growth, and others.

Metabolic
Lysosomal Storage Disorder (LSD) Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

LSD refers to inherited metabolic disorders, which are characterized by enzyme deficiencies. Metachromatic leukodystrophy; Mucolipidosis types I, II/III, and IV; Mucopolysaccharide storage disease; Gaucher disease; Fabry disease; Niemann-Pick disease; Schindler disease types I and II; Tay Sachs disease; Pompe disease; and Sandhoff disease are some of the most common types of LSD.

Metabolic
Hyperlipidemia Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Rise in level of cholesterol is referred as hyperlipidemia, which can be acquired or genetically inherited. There are two types of hyperlipidemia: hypertriglyceridemia (high blood level of triglycerides), and hypercholesterolemia (high blood cholesterol levels).

Metabolic
Diabetic Foot Ulcer Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Diabetic foot ulcer is a serious condition that occurs due to diabetes. It can be defined as ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients.

Metabolic
Mitochondrial-Based Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Mitochondria are the organelles found in cytoplasm of most eukaryotic cells. They are also known as power-house of the cell. Various mitochondrial-related diseases have been discovered, in which the pathogenesis is not understood well.

Metabolic
Wnt Signaling Pathway Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Wnt or β-Catenin signaling pathway plays a key role in the development of pluripotent cells and embryonic development. The pathway regulates cell-to-cell interaction, activates blastocyst, accelerates trophoblast development, accelerate chorion-allantois fusion and implantation.

Metabolic
Galectin Inhibitor Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Galectins belong to the family of animal lectins and perform function by interacting with cytoplasmic and nuclear proteins, cell-surface and extracellular matrix glycoproteins and glycolipids to modulate signalling pathways.

Metabolic
Epidermal Growth Factor Receptor (EGFR) Antagonists Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Epidermal growth factor receptors (EGFR) are a group of receptor tyrosine kinase (RTK) that plays a major role in cell proliferation, survival and differentiation. In most of the cancer, EGFR are amplified and overexpressed, due to dysregulation, resulting in cancer development.

Metabolic
Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Mitogen-activated protein kinase (MAPK) are ubiquitous regulators of many cellular functions including cell proliferation, cellular growth, inflammatory responses to stress signals and cell differentiation.

Metabolic
Hepatocyte Growth Factor (HGF) Inhibitor Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Hepatocyte growth factor (HGF) is secreted by human pancreatic stellate cells and present predominantly on cancer cells. Thus, HGF inhibitors has emerged as an effective therapy in preventing local tumor growth.

Metabolic
RNA Interference (RNAi) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

RNA interference (RNAi) is a molecule type that silences the gene and limits the transcription of the mutated gene. Gene silencing is a novel mechanism that inactivates the transcripts of mutated gene, by activating sequence specific RNA degradation process.

Metabolic
Rho Kinase Inhibitor Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Rho kinase inhibitor, also known as ROCK inhibitor, inhibits the rho kinases, a family of small GTP-binding protein. Rho kinases are found to regulate cell motility, proliferation, shape, gene expression, apoptosis, and are also involved in the signalling pathway.

Metabolic
p53 Antigen Modulators Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

p53 is the tumor suppressor transcription factor that activates to various stimulus, including uncontrolled cell proliferation, oncogene over-expression, and DNA damage. p53 antigen modulators helps in preventing cancer development through regulation of cell cycle and apoptosis.

Metabolic
Cyclophilin Inhibitors Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Cyclophilin befits in the group of protein that shows peptidyl-prolyl cis-trans isomerase activity, found in all types of cells. In humans, 16 cyclophilins have been identified till date. Cyclophilin A, a member of cyclophilin group, mediate the action of immunosuppressive drugs.

Metabolic
Cell Cycle Inhibitors Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Cell cycle inhibitors include cyclin inhibitors and cyclin-dependent kinases (CDKs), which plays major role in developing new class of anti-cancer therapies. Also, cell cycle inhibitors in combination with chemotherapy, overcome drug resistance and improve cytotoxic efficacy. CDKs are rational targets for cancer treatment, that could restore cell-cycle checkpoints and may induce apoptosis.

Metabolic
Aurora Kinase Inhibitor Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Aurora kinase are proteins that function as mitotic regulators and are aberrantly expressed in cancerous cells. Aurora kinase inhibitors target these aberrantly expressed regulators, provides genetic stability and prevents tumorigenesis.

Metabolic
Angiopoietin (ANG) Inhibitors Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Angiopoietin (ANG) receptor plays a crucial role in regulation of vascular permeability and pathological vascular remodelling during tumour angiogenesis, metastasis and inflammation. Thus, it has emerged as a new clinical approach for the development of therapeutics which treat cancer and ophthalmological diseases.

Metabolic
Adenosine 5-Monophosphate Activated Protein Kinase (AMPK) Modulators Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Adenosine 5-monophosphate activated protein kinase (AMPK) plays an important role in regulation of homeostasis. Dysregulation of AMPK can result in many diseases which includes obesity and type 2 diabetes. Several studies have also suggested that AMPK are also associated with the development of neurological diseases and cancer.

Metabolic
Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Akt, also known as PKB, is generally activated in several types of cancers such as breast, gastric, lung, ovary, and pancreatic cancer. Akt inhibitor prevent the functioning of activated form of Akt kinases. Akt kinases are also involved in promoting growth factor-mediated cells that mediates cell proliferation and inhibition of apoptosis through the inactivation of pro-apoptotic proteins, such as mouse double minute 2 homolog (MDM2) and Bcl-2 antagonist of cell death.

Metabolic
Lipodystrophy Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy.

Metabolic
Growth Hormone Deficiency Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Growth hormone deficiency is a congenital or acquired hormonal disorder, that is characterized by short stature due to lack of growth hormone.